VKTX Earnings Date: Feb 10, 2027 (Estimated) — Viking Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is VKTX's next earnings date?
Viking Therapeutics, Inc. (VKTX) is expected to report Q4 2026 earnings on Wednesday, February 10, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.09.
How did VKTX do in its last earnings report?
In its most recent report on Oct 28, 2026 (Q3 2026), Viking Therapeutics, Inc. posted EPS of -$1.55 versus the -$1.06 estimate, a miss of 46.2%. The stock's 1-day post-earnings move was +5.9%.
How much does VKTX stock move after earnings?
VKTX beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.0% (up or down) in the day after earnings.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
🤖 AI Earnings Analysis
VK2735’s obesity program is advancing across subcutaneous Phase 3 trials, with oral Phase 3 now initiated and positive top-line maintenance data—an important catalyst strengthening Viking’s competitive position. The $1.55 quarterly loss missed estimates by $0.49, but pipeline progress outweighs this less-informative biotech metric.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-28 | Q3 2026 | -1.06 | -1.55 | -46.23% | — | ❌ Miss | +5.91% | — | — |
| 2026-07-29 | Q2 2026 | -1.21 | -1.10 | +9.09% | $0 | ✅ Beat | -0.96% | +0.24% | +1.29% |
| 2026-04-29 | Q1 2026 | -0.92 | -1.37 | -48.91% | $0 | ❌ Miss | -0.48% | +3.03% | +4.50% |
| 2026-02-11 | Q4 2025 | -0.90 | -1.38 | -53.33% | $0 | ❌ Miss | +6.80% | +8.93% | +24.80% |
| 2025-10-22 | Q3 2025 | -0.68 | -0.81 | -19.12% | $0 | ❌ Miss | +7.96% | +12.09% | +9.07% |
| 2025-04-23 | Q1 2025 | -0.31 | -0.41 | -32.26% | $0 | ❌ Miss | -0.50% | +11.94% | +7.52% |
| 2024-10-23 | Q3 2024 | -0.25 | -0.22 | +12.00% | $0 | ✅ Beat | +21.25% | +18.81% | -14.51% |
| 2024-07-24 | Q2 2024 | -0.27 | -0.20 | +25.93% | $0 | ✅ Beat | +28.31% | +13.07% | +27.65% |
Showing last 8 quarters.